News & Reports

News and Reports

IP Watchdog: Current and Former Lawmakers Lock Horns in Comments on USPTO’s Proposed PTAB Changes

Patients For Affordable Drugs (P4AD)“strongly oppose[s]” the proposed rule because, according to their submission, the PTAB “allows for more efficient, accessible, and affordable challenges to invalid patents,” particularly in the context of pharmaceutical patents. Prior to the American Invents Act (AIA), said P4AD, invalidating pharma patents “cost millions of dollars in district courts, harmed many communities, […]

News and Reports

Inside Health Policy: CMS Will Drop Three Part D Drugs From IRA Pricing Program In 2027

The upcoming removal of Entresto, Stelara and Xarelto from the negotiation program appears to be consistent with the inflation Reduction Act’s procedure for dropping drugs once competition enters the market. “The Medicare Negotiation Program was designed to serve as a check on the monopoly power of the pharmaceutical industry and the highest-cost and most commonly […]

News and Reports

Inside Health Policy: Trump’s CMS Secures Steeper MFPs For Second Round Of Negotiated Drugs

“This second round of negotiations marks another major milestone, delivering continued savings for patients that are consistent with the first round, and reinforcing that the Medicare Negotiation Program works. The inclusion of high-cost drugs like GLP-1s and more medications negotiated this round also means that savings to Medicare and taxpayers increased. Medicare negotiation is hugely […]

News and Reports

KFF Health News: FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office

Judy Aiken, a retired Portland, Maine, nurse who has taken Enbrel since 2007 to treat psoriatic arthritis, would be interested in trying the copycat if it costs her less. After retiring in 2019 and going on Medicare, she has spent thousands each year on the drug. The Biden-era Inflation Reduction Act capped her out-of-pocket drug […]

News and Reports

Jacobin: How Big Pharma Turned FDA Approval Into a Rubber Stamp

Drug company employees with titles like “director of patient engagement” carefully cultivate relationships with advocacy groups. Some patient groups are led by executives on “loan” from industry, according to a study published in 2020, and nearly 40 percent have a pharmaceutical executive on their boards. Another study, by Patients for Affordable Drugs, the rare advocacy group that does not […]

News and Reports

Epoch Times: What to Know About Trump’s Pharma Deals to Lower Prices

“The Most Favored Nation agreements we’ve seen so far are voluntary, confidential, and apply only to Medicaid—a program through which most patients pay less than $4 per prescription,” Merith Basey, executive director of Patients for Affordable Drugs, told The Epoch Times. “Pharmaceutical executives are touting these industry-friendly agreements, while they continue to fight systemic reform […]

News and Reports

Reuters: Exclusive: US pharmacies, drug discounters are discussing TrumpRx role with administration

Jacquie Persson, a graphic designer in Cedar Rapids, Iowa, said a drugmaker-issued discount card cut her co-pay for an expensive migraine drug to $5 from about $100. “I’m really lucky to have good insurance through my employer. My husband’s insurance isn’t as good,” she said. “I am a chronically ill individual … it is a […]

News and Reports

IP Watchdog: Novo Nordisk Challenges to CMS Single Source Drug Determinations Fall to IRA’s Bar Against Judicial Review

Patient advocacy group, Patients for Affordable Drugs (P4AD), celebrated the ruling, noting in a statement that this marks the 15th legal defeat for the industry on this issue.